ArticleTranslational cancer research2019
Knockdown of RPL34 suppresses osteosarcoma cell proliferation likely through EIF3/FAU signaling pathway.
Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- The Interplay Between theInternational journal of molecular sciences · 2024Review
- Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics.bioRxiv : the preprint server for biology · 2023Article
- URG4 mediates cell proliferation and cell cycle in osteosarcoma via GSK3β/β-catenin/cyclin D1 signaling pathway.Journal of orthopaedic surgery and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to explore the effect of knockdown of the ribosomal protein L34 (RPL34) on osteosarcoma cell proliferation through EIF3/FAU.
methodsThe mRNA expression levels of RPL34, EIF3A, EIF3F, EIF3G, UBA52, UBC, and FAU were quantified using quantitative real-time PCR (qRT-PCR) in two human cell lines: the hFOB1.19 osteoblast cell line and the Saos-2 osteosarcoma cell line. The qRT-PCR analysis was performed to confirm the shRNA-mediated depletion of RPL34, and a western blot analysis was done to confirm the knockdown of protein levels. qRT-PCR was also used to examine the effects of RPL34 knockdown on the above genes.
resultsThe mRNA expression levels of RPL34, EIF3A, EIF3G, UBA52, UBC, and FAU were increased in the Saos-2 cells relative to the hFOB1.19 osteoblast cells. EIF3F expression was decreased in Saos-2 cells relative to hFOB1.19 cells. Knockdown of RPL34 mRNA significantly suppressed EIF3A and EIF3F expression and significantly up-regulated FAU expression in the Saos-2 cell line, but there were no remarkable differences in the relative expression in the EIF3G, UBA52, and UBC genes.
conclusionsKnockdown of RPL34 suppresses osteosarcoma cells proliferation probably through EIF3A, EIF3F, and FAU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.